Abstract
This paper summarizes international clinical experience with the next generation of statins, pitavastatin, in dyslipidemias. This medication is effective at a dose of 1–4 mg in most patients (including comorbid patients) compared to other statins. Pitavastatin affects various parameters of the lipid profile (i.e., total cholesterol, high-density, low-density, and very-low-density lipoprotein cholesterol, triglycerides, apolipoproteins) and provides pleotropic effects (plaque stabilization, reduction in the levels of systemic inflammatory markers, antithrombotic and antidiabetic effects etc.). The unique structure of this medication and its metabolism account for the minimal risk of adverse effects (AEs) or drug interactions. Hence, pitavastatin is recommended for elderly and senile patients with senile asthenia, patients receiving multiple therapies or individuals with intolerance to other statins. Pitavastatin is prescribed as monotherapy or along with ezetimibe. Long-term taking is associated with the reduction in the rate of cardiovascular events and minimal AEs. This case report (a 65-year-old woman with dyslipidemia, comorbidities, and high cardiovascular risk) illustrates the efficacy and safety of pitavastatin. KEYWORDS: dyslipidemia, hypercholesterolemia, comorbidity, lipid-lowering therapy, high cardiovascular risk. FOR CITATION: Sedykh D.Yu., Khryachkova O.N., Kashtalap V.V., Barbarash O.L. Treatment for dyslipidemia in comorbid patients in real clinical practice: potentialities of pitavastatin. Russian Medical Inquiry. 2021;5(4):218–224 (in Russ.). DOI: 10.32364/2587-6821- 2021-5-4-218-224.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
